Netherlands· NL-2a9d2d8d58ee
ZINPLAVA 25 mg/ml, concentraat voor oplossing voor infusie
A bezlotoxumab product containing bezlotoxumab, registered in Netherlands by Merck Sharp & Dohme B.V.. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Bezlotoxumab is registered in 9 of 19 countries.
Countries holding a registration under ATC J06BC03 (bezlotoxumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Bezlotoxumab · ATC J06BC03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- BEZLOTOXUMAB
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Netherlands (NL)
- ATC code
- J06BC03
- ATC class
- Bezlotoxumab
- Defined daily dose
- 0.7 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/16/1156
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bezlotoxumab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceZINPLAVA 25 mg/mL, solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- BelgiumZinplava 25 mg/mlMerck Sharp & Dohme
- CzechiaZINPLAVAMerck Sharp & Dohme B.V., Haarlem
- SpainZINPLAVA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZINPLAVAMerck Sharp & Dohme B.V.
- United KingdomZinplava 1g/40ml concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZINPLAVA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme BV
- IcelandZinplavaMerck Sharp & Dohme B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zinplava
- Liechtenstein · Zinplava
- Norway · Zinplava
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b031e3c9-195b-4705-84a8-03342794b913 GET /v1/drugs/b031e3c9-195b-4705-84a8-03342794b913?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/zinplava-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Bezlotoxumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp118465",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"NATRIUMCHLORIDE",
"PENTETINEZUUR",
"POLYSORBAAT 80 (E 433)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"BEZLOTOXUMAB"
],
"leaflet_url": null,
"authorised_at": "2017/01/18",
"procedure_number": "EMEA/H/C/004136",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/16/1156",
"additional_monitoring": "N"
}See everything about bezlotoxumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.